GLP-1 Receptor Agonists: Changing the Scales of Human Health
Presented by RGA
Glucagon-like peptide 1 receptor agonists (GLP-1s) may be poised to become an integral part of treating a range of chronic diseases – from cardiovascular disease to cancer – and could improve all-cause mortality rates.